<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Abnormal <z:chebi fb="6" ids="39025">high-density lipoproteins</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) metabolism is a major <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factor</z:e> in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Lecithin:cholesterol acyltransferase (LCAT) increases <z:chebi fb="17" ids="39025">HDL</z:chebi> size by transferring 2-<z:chebi fb="0" ids="22221">acyl groups</z:chebi> from lecithin or <z:chebi fb="0" ids="16038">phosphatidylethanolamine</z:chebi> to unesterified cholesterol </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to determine the independent correlates of LCAT activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A total of 45 (male: 20) consecutive adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> patients aging 50.0+/-7.0 years (range: 40-64 years) with a median <z:mp ids='MP_0002055'>diabetes</z:mp> duration of 4 years (range: 2-18) were studied </plain></SENT>
<SENT sid="4" pm="."><plain>Exclusion criteria were: smoking, positive history of cardiovascular, thyroid, renal or <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e>, pregnancy, treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi>, insulin, <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering drugs, <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi>, aspirin or <z:chebi fb="11" ids="22586">antioxidant</z:chebi> supplements </plain></SENT>
<SENT sid="5" pm="."><plain>Univariate and multivariate analyses were performed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: From a comprehensive list of variables studied, only HbA1c (rho=-0.951) and oxidized <z:chebi fb="15" ids="39026">LDL</z:chebi> (rho=-0.779) had statistically significant correlation with LCAT activity (p&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>These two variables were themselves strongly correlated to each other (rho=0.809, p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>To eliminate potential confounding effects, we performed multivariate analysis, where HbA1c emerged as a strong independent predictor of LCAT activity (adjusted OR=-0.928, p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Glycemia-induced glycation of <z:chebi fb="17" ids="39025">HDL</z:chebi> decreases LCAT activity </plain></SENT>
<SENT sid="10" pm="."><plain>The fact that HbA1c is an accurate measure of glycation and can therefore reflect glycated <z:chebi fb="17" ids="39025">HDL</z:chebi> levels explains the association found in the present study </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, HbA1c provides an easy-to-assess, accurate measure of LCAT activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> </plain></SENT>
</text></document>